Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.73 |
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | S100B | P04271 | 1/20 | 0.63 |
| ▸ | F3 | P13726 | 2/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330111 | 1.00 | THRB (0.73) | THRBATMS100BF3PTGS2 | |
| SCHEMBL13476143 | 0.88 | S100B (0.63) | THRBATMS100BF3PTGS2 | |
| SCHEMBL21166344 | 0.87 | THRB (0.53) | THRBATMS100BPTGS2PTGS1 | |
| 4-Methoxycinnamic Acid SCHEMBL58699 | 0.86 | THRB (1.00) | THRBATMF3PTGS2GSK3B | |
| 4-Methoxycinnamic Acid SCHEMBL58700 | 0.86 | THRB (1.00) | THRBATMF3PTGS2GSK3B | |
| 4-Methoxycinnamic Acid SCHEMBL12473722 | 0.86 | THRB (1.00) | THRBATMF3PTGS2GSK3B | |
| SCHEMBL9556747 | 0.85 | NPC1 (0.56) | THRBATMNPC1RAB9AALDH1A1 | |
| 4-Methoxycinnamic Acid SCHEMBL5330596 | 0.84 | THRB (0.96) | THRBATMF3PTGS2GSK3B | |
| 4-Methoxycinnamic Acid SCHEMBL10935651 | 0.84 | THRB (0.96) | THRBATMF3PTGS2GSK3B | |
| 4-Methoxycinnamic Acid SCHEMBL8500105 | 0.84 | THRB (0.96) | THRBATMF3PTGS2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209748-A1 | METAL ORGANIC LIQUID CRYSTAL DYES | Gauzy Ltd (IL) | 2017-08-30 | — | — | EP | disclosed |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
| WO-2008094319-A2 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYTEM (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | THRB 1013/4885ATM 1566/4885S100B 4126/4885 |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | THRB 1013/4885ATM 1566/4885S100B 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.